Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isodiol International Inc ISOLF

Healthcare Drug Manufacturers - Specialty & Generic Cannabis
Isodiol International Inc is a manufacturer and developer of phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. It generates revenue from the sale of nutritional health products derived from hemp. Geographically, it derives a majority of revenue from the United States and also has a presence in Canada. Its product categories include Tinctures; Capsules; Topicals; Vape; Oral Spray; Skincare; and others.


GREY:ISOLF - Post by User

Isodiol International Inc
Bullboard Posts
User Avatar Image
(76)
•••
Comment by Isodog2018on Aug 16, 2019 7:37pm
161 Views
Post# 30038585

RE:15m market cap and a 9m quarter

RE:15m market cap and a 9m quarter
NotBornLastNite wrote: the future is ours.



Sweet


“We have just realized our most profitable quarter to date and have reduced our operating expenses considerably, which will be seen in the first quarter of FY2020,” said CEO of Isodiol, Marcos Agramont.  “The majority of losses experienced in FY 2019 are a by-product of our shift in our focus towards higher margin consumer products vs raw ingredient supply, prevention of massive shareholder dilution and protecting our future cash flows through divestitures.” Marcos went on, “Over the last several months we have sharpened our focus significantly, cut costs, curbed shareholder dilution and we believe the Company is in a strong position heading into FY2020 and beyond."

KISS $$$

Cheers!
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities